March 28, 2025 8:17am

But I am staying-sideline of the big “casino” today; inflation econs keep me wordless coming off a losing session for the major averages and alternating sector closes

As I wrote last night, “risk is still squatting, whether you realize it-or-not, the skin of indexes and share pricing as sector reverses to close Thursday positive.”

 News: Bluebird Bio (BLUE) will be acquired by investment firms Carlyle and SK Capital Partners, marking the end to its turbulent time. The agreement comes after years of financial struggles, declining stock performance, and mounting cash flow concerns, with the investment firms stepping in to provide the necessary capital to keep bluebird’s gene therapy program afloat

 

Breaking News: The Fed’s key inflation measure rose more than expected in February while consumer spending also posted a smaller than projected increase. The core personal consumption expenditures price index showed a 0.4% increase for the month, putting the 12-month inflation rate at 2.8%. Economists surveyed by Dow Jones had been looking for respective numbers of 0.3% and 7% Core inflation excludes volatile food and energy prices and is generally considered a better indicator of long-term inflation trends.  In the all-items measure, the price index rose 0.3% on the month and 2.5% from a year ago, both in line with forecasts. At the same time, the Bureau of Economic Analysis report showed that consumer spending accelerated 0.4% for the month, below the 0.5% forecast. That came as personal income posted a 0.8% rise, against the estimate for 0.4%.

No false narratives or fake news; to read insights and analysis on the latest sector action, check out Pre-Open Brief …

Never leave an investor uninform

 

Remember that overnight and pre-open actions’ futures and markets doesn’t necessarily translate into actual trading in today’s market session.

My interpretation of the morning’s numbers is written to be informative; it’s built on what happened to make “it” happen today!

 

Thursday’s night’s … RegMed Investors (RMi) Closing Bell: risk is still squatting … https://www.regmedinvestors.com/articles/13857

 

Friday; the pre-open Dow futures are DOWN -0.10% or (-39 points), the S&P futures are DOWN -0.14 or (-7 points) and the Nasdaq futures are DOWN -0.23% or (-44 points)

  • U.S. stock futures edged lower on Friday, 3/28
  • European stock markets traded lower.
  • Asia-Pacific markets mostly fell.

 

Henry’omics: We need to more than consider the economic environment to comprehend the micro re “our” universe of cell and gene therapy companies

  • Thursday: The pre-open Dow futures are UP +0.12 or (-53 points), the S&P futures are DOWN -0.09% or (-5 points) and the Nasdaq futures are DOWN -0.19% or (-38 points)

Economic Data Docket: Personal Consumption Expenditures Index (PCE) and core PCE and University of Michigan's Consumer Sentiment Index

  • Economists exoect the headline PCE price index reading rising 0.3% in February and 2.5% from 12 months earlier.

 

Q1/25:  March sessions with 10 positive and 10 negative closes

  • February – 1 holiday, 11 negative and 8 positive closes
  • January – 2 holidays, 1 market close, 10 negative and 10 positive closes

Q4/24:

  • December 1 holiday, 15 negative and 5 positive closes
  • November 10 negative and 9 positive closes
  • October: 8 positive and 15 negative closes

 

Companies in my headlights – It’s your decision; I provide ideas and context

I post about “indication intelligence” looking toward investment conferences … to assist investors with insight into sector vulnerabilities and strengths.

A dictionary definition of “indicate” refers to something less than a certainty; an indication could be a signal of being oversold or overbought, a recommendation, or grounds for inferring or a basis for believing.

Better part of valor to not lead any investor to temptation; yet again, I am passing on forecasting the daily indications as to expectation while the aftermarket blanked while the pre-open waits for the …  econs, it is still a mix of ups, downs and just uncertainty.

 

The BOTTOM LINE: the last full week …

  • the 4th of March …Monday closed positive followed by negative closes on Tuesday and Wednesday …Friday and Thursday closed negative after Wednesday closed positive, Tuesday closed negative following Monday’s positive close
  • A positive Friday sector close following Thursday’s negative close after 2 positive (Wednesday & Tuesday) closes following Monday’s negative close.
  • The previous Friday, 3/7 – the 5th NEGATIVE session in the week intermingled by 1 POSITIVE (Wednesday) close in a new month of March … so, what moves stock pricing

As I have written, “uncle algo and his trading dwarfs” will determine the heights or lows of share pricing”

March to date:

  • 3/27 – Thursday closed positive with 22 positive, 10 negative and 3 flats
  • 3/26 – Wednesday closed negative with 3 positive, 28 negative and 4 flats
  • 3/25 - Tuesday closed negative with 7 positive, 25 negative and 3 flats
  • 3/24 - Monday closed positive with 31 positive, 3 negative and 1 flat
  • 3/21 – Friday closed positive with 17 positive, 16 negative and 2 flats
  • 3/20 – Thursday closed negative with 10 positive, 23 negative and 2 flats
  • 3/19 - Wednesday closed positive with 25 positive, 8 negative and 2 flats
  • 3/18 - Tuesday closed negative with 7 positive, 27 negative and 1 flat
  • 3/17 – Monday closed positive with 24 positive, 10 negative and 1 flat
  • 3/14 – Friday closed positive with 20 positive, 13 negative and 2 flats
  • 3/13 - Thursday closed negative with 4 positive, 30 negative and 1 flat
  • 3/12 – Wednesday closed positive with 25 positive, 9 negative and1 flat
  • 3/11 - Tuesday closed positive with 23 positive, 11 negative and 1 flat
  • 3/10 – Monday closed negative with 3 positive, 31 negative and 1 flat
  • 3/7 – Friday closed negative with 14 positive, 17 negative and 4 flats
  • 3/6 – Thursday closed negative with 16 positive, 18 negative and 1 flat
  • 3/5 – Wednesday closed positive with 25 positive, 9 negative and 1 flat
  • 3 /4 – Tuesday closed negative with 15 positive, 18 negative and 2 flats
  • 3/3 – Monday closed negative with 2 positive, 31 negative and 2 flats

 

Reiterating, “I think it's important just to take a step back, focus on the fundamentals, be selective. I mean, this has definitely been a “sucky” January and February from a stock-picker standpoint given the up/downs. And so, I am relatively neutral across today/Friday’s equity strategy.

•             Reiterating, “Take the emotion out of the sector, think of the reality of the “plays” that exist of who’s really buying.”

It’s all but OVER … earnings season “sparked” a quarterly life crisis…

•             Think about it; one of the biggest problems with the cell and gene therapy sector’s share pricing is …  99% of them have no earnings! If rates are higher for longer, that means that sector companies will continue to struggle or be unable to raise capital and therefore be subject.

 

Welcome to my world of defining the “grey’ in our universe!

•             The sector is what it is, until it isn’t and even then, it doesn’t seem to be… as NOT much changes as the sector’s share pricing rides the waves of volatility, algorithms, electronic trading and short covering.

•             I am more frequently right than consequentially wrong; if I wanted to be liked, I wouldn’t have been an analyst/journalist.

 

Opinions expressed are those of the author and are subject to change, and not intended to be a forecast of future events, a guarantee of future results, nor investment advice. All investments are subject to risks. Investors should consider investment objectives.

Whether information or intelligence is good, bad or somewhere in between; I put into context what is relevant and useful for investors.  All investments are subject to risks. Investors should consider investment objectives.  Regulation Analyst Certification (Reg AC): The research analyst primarily responsible for the content of this report certifies the following under Reg AC: I hereby certify that all views expressed in this report accurately reflect my personal views about the subject company or companies and it’s or their securities. I also certify that no part of my compensation was, is or will be, directly or indirectly, related to the specific recommendations or views expressed in this report.

Henry McCusker, the editor and publisher of RegMed Investors could hold or have positions securities referred to in this publication and he will NOTIFY investors of holdings.